Echo IQ (EIQ) Q2 2026 TU earnings summary

Executive summary

• Achieved major milestones in US market commercialisation, including clinical validation and FDA submission for EchoSolv HF.

• Mayo Clinic Platform Validate program confirmed EchoSolv HF's high diagnostic accuracy, meeting and exceeding primary endpoints.

• Strategic US presence strengthened with appointments of leading cardiologists as advisors.

Financial highlights

• Cash and cash equivalents at 31 December 2025 were $13.21 million.

• Net cash used in operating activities for the quarter was $2.67 million.

• Payments to related parties during the quarter totaled $160,000.

• Estimated 4.95 quarters of funding available based on current cash burn.

Outlook and guidance

• Focused on securing FDA clearance for EchoSolv HF and advancing reimbursement strategy in the US.

• Plans to expand adoption of EchoSolv platforms in the US and enter large international markets, including the EU.